Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIZENS FINANCIAL GROUP INC/RICFG · Entity 1913 | Director | February 14, 2019 | February 15, 2019 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIZENS FINANCIAL GROUP INC/RI
Report date February 14, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,993.604 |
Reported balance
After 2019-02-14 transaction · row 1
1 source rowRow 1 · 2019-02-14 · Grant · Acquired 30.91 · Balance 60,993.604 F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan.
REGENERON PHARMACEUTICALS, INC.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,303 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 200 · Balance 17,303 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2026 Filed Jul 7, 2026 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $650.15 | $130,030.00 |
DisclosureSEC source: 0001187443-26-000010 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,303 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $714.13 | $1,428.26 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,503 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F12 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $714.12 to $714.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $712.09 | $712.09 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,505 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $711.49 | $3,557.45 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,506 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F11 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $711.17 to $711.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $710.87 | $1,421.74 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,511 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F10 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $710.86 to $710.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $709.45 | $4,256.70 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,513 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F9 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on May 1, 2026 at prices ranging from $709.05 to $709.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $707.40 | $2,829.60 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,519 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F8 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on May 1, 2026 at prices ranging from $707.12 to $707.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $706.74 | $4,947.18 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,523 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F7 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on May 1, 2026 at prices ranging from $706.05 to $706.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $705.56 | $9,877.84 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,530 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F6 · price: Represents volume-weighted average price of sales of 14 shares of Company stock on May 1, 2026 at prices ranging from $705.02 to $705.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15 | $704.28 | $10,564.20 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,544 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F5 · price: Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $704.01 to $704.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 24 | $703.46 | $16,883.04 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,559 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F4 · price: Represents volume-weighted average price of sales of 24 shares of Company stock on May 1, 2026 at prices ranging from $703.01 to $703.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15 | $702.46 | $10,536.90 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,583 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F3 · price: Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $702.02 to $702.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $701.76 | $3,508.80 |
DisclosureSEC source: 0001187443-26-000008 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,598 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $701.36 to $701.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 40 | $779.71 | $31,188.40 |
DisclosureSEC source: 0001104659-26-039613 · tm2611142-1_4seq1.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,603 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F9 · price: Represents volume-weighted average price of sales of 40 shares of Company stock on April 1, 2026 at prices ranging from $779.65 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $778.24 | $3,112.96 |
DisclosureSEC source: 0001104659-26-039613 · tm2611142-1_4seq1.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F8 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2026 at prices ranging from $778.02 to $778.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $777.42 | $6,996.78 |
DisclosureSEC source: 0001104659-26-039613 · tm2611142-1_4seq1.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,647 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F7 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on April 1, 2026 at prices ranging from $777.03 to $777.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13 | $776.62 | $10,096.06 |
DisclosureSEC source: 0001104659-26-039613 · tm2611142-1_4seq1.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,656 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F6 · price: Represents volume-weighted average price of sales of 13 shares of Company stock on April 1, 2026 at prices ranging from $776.11 to $776.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $775.58 | $10,858.12 |
DisclosureSEC source: 0001104659-26-039613 · tm2611142-1_4seq1.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,669 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F5 · price: Represents volume-weighted average price of sales of 14 shares of Company stock on April 1, 2026 at prices ranging from $775.04 to $775.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $774.58 | $6,196.64 |
DisclosureSEC source: 0001104659-26-039613 · tm2611142-1_4seq1.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,683 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F4 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2026 at prices ranging from $774.05 to $774.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $773.59 | $6,188.72 |
DisclosureSEC source: 0001104659-26-039613 · tm2611142-1_4seq1.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,691 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F3 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2026 at prices ranging from $773.27 to $773.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $772.76 | $2,318.28 |
DisclosureSEC source: 0001104659-26-039613 · tm2611142-1_4seq1.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,699 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on April 1, 2026 at prices ranging from $772.62 to $772.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $771.32 | $771.32 |
DisclosureSEC source: 0001104659-26-039613 · tm2611142-1_4seq1.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,702 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 20 | $789.28 | $15,785.60 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,703 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F13 · price: Represents volume-weighted average price of sales of 20 shares of Company stock on March 2, 2026 at prices ranging from $789.27 to $789.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 20 | $788.96 | $15,779.20 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,723 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $787.34 | $1,574.68 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,743 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F12 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $787.02 to $787.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $786.61 | $5,506.27 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,745 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F11 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $786.12 to $786.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $785.48 | $8,640.28 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,752 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F10 · price: Represents volume-weighted average price of sales of 11 shares of Company stock on March 2, 2026 at prices ranging from $785.02 to $785.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $784.48 | $7,060.32 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,763 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F9 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on March 2, 2026 at prices ranging from $784.02 to $784.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $783.62 | $7,836.20 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,772 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F8 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on March 2, 2026 at prices ranging from $783.25 to $783.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $782.62 | $1,565.24 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,782 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F7 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $782.25 to $782.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $781.21 | $1,562.42 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,784 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F6 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $781.00 to $781.42. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $780.69 | $2,342.07 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,786 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F5 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on March 2, 2026 at prices ranging from $780.13 to $780.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $779.69 | $3,898.45 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,789 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F4 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on March 2, 2026 at prices ranging from $779.36 to $779.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $778.30 | $1,556.60 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,794 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F3 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $778.27 to $778.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $777.46 | $5,442.22 |
DisclosureSEC source: 0001187443-26-000006 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,796 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $777.08 to $777.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $787.82 | $787.82 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,803 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $786.29 | $1,572.58 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,804 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $785.71 | $785.71 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,806 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $784.59 | $784.59 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,807 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $783.34 | $2,350.02 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,808 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F7 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on February 9, 2026 at prices ranging from $783.20 to $783.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $782.53 | $782.53 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,811 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $781.48 | $3,907.40 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,812 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F6 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $781.05 to $781.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $780.09 | $780.09 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,817 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $779.41 | $3,897.05 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,818 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F5 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $779.13 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $778.53 | $9,342.36 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,823 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F4 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on February 9, 2026 at prices ranging from $778.11 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 57 | $777.56 | $44,320.92 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,835 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F3 · price: Represents volume-weighted average price of sales of 57 shares of Company stock on February 9, 2026 at prices ranging from $777.02 to $777.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $776.59 | $7,765.90 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,892 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on February 9, 2026 at prices ranging from $776.04 to $776.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $775.63 | $775.63 |
DisclosureSEC source: 0001187443-26-000004 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,902 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,962 | $0.00 Strike: $772.76 | $0.00 |
DisclosureSEC source: 0001187443-26-000002 · edgardoc.xml · derivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 1,962 shares Expires 2036-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001187443-26-000002 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,903 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.